PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.
Ana Maria OrbaiRichard HollandYing Ying LeungWilliam TillettNiti GoelRobin ChristensenNeil McHughLaure GossecMaarten P T de WitPil HøjgaardLaura C CoatesPhilip J MeaseJulie BirtLara FallonOliver FitzGeraldPhilip S HelliwellBeverly SheaVibeke StrandKristina Callis DuffinPeter TugwellDorcas BeatonDafna D GladmanPublished in: The Journal of rheumatology (2018)
At OMERACT 2018, PsAID12 was the first patient-reported outcome measure provisionally endorsed as a core outcome measure for disease-specific HRQOL in PsA clinical trials. PsAID12 discrimination and improvement thresholds will be studied in future RCT.